How Turning ‘Cold’ Tumors Into ‘Hot’ Ones May Improve Response to Immunotherapy
The proliferation of immunotherapeutics in the treatment of cancer over the past decade has revolutionized the way many cancers are treated, especially lung cancer and melanoma...
Novel Treatments of Myelodysplastic Syndromes
As part of The ASCO Post’s continued coverage of the 2018 American Society of Hematology Annual Meeting & Exposition, here is an update on seven different studies on new therapeutics...
Encourage Lung Cancer Screening to Prevent Early Deaths
Discussions of benefits and harms from screening of high-risk populations for lung cancer have missed the point. The National Lung Screening Trial (NLST) showed an early and statistically significant...
Lorlatinib Shows Overall and Intracranial Activity in ALK-Positive NSCLC
In a global phase II study reported in The Lancet Oncology, Benjamin J. Solomon, MBBS, of Peter MacCallum Cancer Centre, Melbourne, and colleagues found that lorlatinib...
Living My Best Life
But then my life took a drastic turn. Suddenly, a lump popped up on the left side of my neck, which I initially attributed to my body’s way of fighting off an infection...
Allen Lichter: The Potential of Value-Based Prescribing in Oncology
Karen Reckamp: PACIFIC Trial of Durvalumab in Stage III Unresectable NSCLC
Damien Hansra: Breast Cancer Surgical Terminology Update
Thomas Witzig: Essential Elements of an Effective Clinical Trials System
Fred Hirsch: Progress With ALK Inhibitors
More Top Stories
Integrative Oncology Scholars Program: Model for Evidence-Based Complementary Care
THE FIRST full year of educational training in the practice of complementary therapies is now underway at the University of Michigan in Ann Arbor through its Integrative Oncology Scholars Program, which launched in 2017. The program, which is supported through a 5-year grant from the National...
New Approach to Predicting Response to Pertuzumab and Trastuzumab in Breast Cancer
In the phase II TBCRC026 study reported in the Journal of Clinical Oncology, Connolly et al found that early changes in tumor maximum standardized uptake values corrected for lean body mass (SULmax) on [18F]fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) were...
FDA Approves Ibrutinib in Combination With Obinutuzumab in Treatment-Naive CLL/SLL
ON JANUARY 28, 2019, the U.S. Food and Drug Administration (FDA) approved ibrutinib (Imbruvica), a Bruton’s tyrosine kinase inhibitor, in combination with obinutuzumab in treatment-naive patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). This is the first approval of ...
New ASCO Answers Fact Sheet: When the Doctor Says ‘Cancer’
People diagnosed with cancer often say they were stunned when they heard the news of their diagnosis, and were unable to process what their health-care provider said afterward. Give your patients easy-to-understand information they can take home with them. When the Doctor Says “Cancer” is a 1-page...
Involvement of Primary Care Providers in Cancer Treatment Decisions
The idea of team-based cancer care most often focuses on involving primary care physicians in the care of cancer survivors, but research has shown patients are also discussing initial cancer treatment options with their primary care doctors. Now, a new study by Wallner et al in Cancer has...
Clinical Cancer Advances 2019: ASCO Names Advance of the Year, Debuts Research Priorities for the Cancer Community
In the release of its annual report on progress against cancer, Clinical Cancer Advances 2019, ASCO recognized progress in treating rare cancers as the Advance of the Year. The report catalogs a year’s worth of remarkable research advancements, reinforces the need for continued federal research...
System-Based Intervention to Reduce Racial Disparities in Early-Stage Lung Cancer Treatment
Results from a study published by Cykert et al in Cancer Medicine showed that a pragmatic system-based intervention within cancer treatment centers may eliminate existing disparities in treatment and outcomes for black patients with early-stage lung cancer. “These results show ...
Andrew X. Zhu, MD, PhD, on Liver Cancer: Outcomes in the REFLECT Study on Lenvatinib
Shoshana M. Rosenberg, ScD, on Quality of Life and the Impact of Breast Cancer Surgery
Robert A. Figlin, MD, on RCC: Results From the ADAPT Trial
Carl C. Schimanski, MD, PhD, on Colorectal Cancer Liver Metastases: Study Results on Tecemotide After Surgery
